- Home
- ASR vs ROIV Comparison
ASR vs ROIV Comparison
Compare ASR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASR
- ROIV
- Stock Information
- Founded
- ASR 1996
- ROIV 2014
- Country
- ASR Mexico
- ROIV United Kingdom
- Employees
- ASR N/A
- ROIV N/A
- Industry
- ASR Aerospace
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- ASR Consumer Discretionary
- ROIV Health Care
- Exchange
- ASR Nasdaq
- ROIV Nasdaq
- Market Cap
- ASR 9.7B
- ROIV 8.6B
- IPO Year
- ASR 2000
- ROIV N/A
- Fundamental
- Price
- ASR $346.01
- ROIV $14.08
- Analyst Decision
- ASR Buy
- ROIV Strong Buy
- Analyst Count
- ASR 2
- ROIV 4
- Target Price
- ASR $310.00
- ROIV $15.50
- AVG Volume (30 Days)
- ASR 92.6K
- ROIV 6.6M
- Earning Date
- ASR 10-21-2025
- ROIV 11-11-2025
- Dividend Yield
- ASR 6.68%
- ROIV N/A
- EPS Growth
- ASR 3.79
- ROIV N/A
- EPS
- ASR 2.20
- ROIV N/A
- Revenue
- ASR $1,803,288,586.00
- ROIV $23,233,000.00
- Revenue This Year
- ASR $14.80
- ROIV N/A
- Revenue Next Year
- ASR $10.10
- ROIV $281.14
- P/E Ratio
- ASR $15.74
- ROIV N/A
- Revenue Growth
- ASR 21.26
- ROIV N/A
- 52 Week Low
- ASR $248.88
- ROIV $8.73
- 52 Week High
- ASR $360.00
- ROIV $14.48
- Technical
- Relative Strength Index (RSI)
- ASR 68.11
- ROIV 76.40
- Support Level
- ASR $335.03
- ROIV $11.85
- Resistance Level
- ASR $344.05
- ROIV $14.48
- Average True Range (ATR)
- ASR 7.67
- ROIV 0.42
- MACD
- ASR 1.14
- ROIV 0.21
- Stochastic Oscillator
- ASR 83.19
- ROIV 86.26
About ASR Grupo Aeroportuario del Sureste S.A. de C.V.
Grupo Aeroportuario del Sureste SAB de CV and its subsidiaries hold concessions to operate, maintain, and develop airports in the southeast region of Mexico. As an operator of airports, it charges airlines, passengers, and other users fees for using the airports' facilities. The group also derives rental and other income from commercial activities conducted at its airports, such as the leasing of space to restaurants and retailers. The group's operating segments are Cancun, which generates maximum revenue, Aerostar, Airplan, Merida, Villahermosa, Holding and Services, and Others.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.